Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Boyd

, Fremming

. Rimonabant—a selective CB1 antagonist. Ann Pharmacother 2005;39:684–90. Epub 8 Mar 2005. DOI 10.1345/aph.1E499

VanGaal

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patient: 1 year experience from the RIO-Europe study. Lancet 2005;365:1389.

Despres

, Golay

, Sjostrom

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353;20:2121–34.

Update on Rimonabant—A Selective Cannabinoid CB1 Antagonist

Abstract

Get full access to this article

References